NCART Now Sharing Updates Via YouTube
The National Coalition for Assistive & Rehab Technology (NCART) has created a YouTube channel.
In an April 3 newsletter to stakeholders, NCART — @NCART-CRT — introduced the channel. Its first video is a greeting from Executive Director Wayne Grau, who said, “This is an incredible opportunity to share with everyone the value that Complex Rehab Technology brings to individuals who need this type of equipment.
“Videos share the experiences of the consumers and how they’re able to get out, enjoy their lives, go to school, go to church, go to work, do the things they need to do to live the lives that they want to,” Grau added.
Relyvrio ALS Treatment Withdrawn from US, Canada After Research Results
Relyvrio, an approved treatment for amyotrophic lateral sclerosis (ALS), has been withdrawn from the American and Canadian markets by its manufacturer based on phase 3 PHOENIX trial results.
Amylyx Pharmaceuticals voluntarily removed the add-on medication, known as Albrioza in Canada, on April 4 after research showed patients with ALS who took Relyvrio “experienced a similar rate of disease progression as those given a standard treatment alone,” ALS News Today reported on April 5.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS and other neurodegenerative diseases,” said Amylyx co-CEOs Joshua Cohen and Justin Klee in an April 4 news announcement. “The decision to remove RELYVRIO/ALBRIOZA from the market and provide therapy free of charge for those who wish to continue was informed by the PHOENIX trial results, engagement with regulatory authorities, and discussions with the ALS community. Thank you to each and every person who shared feedback with us and continues to support our commitment to the ALS community.”
